AddThis Feed Button "Frequently Copied, Never Duplicated"

Thursday, April 29, 2010

Death Effects and Schizophrenia Drugs

MEDLINE Abstract

--------------------------------------------------------------------------------
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Lancet. 2009; 374(9690):620-7 (ISSN: 1474-547X)
Tiihonen J ; Lönnqvist J ; Wahlbeck K ; Klaukka T ; Niskanen L ; Tanskanen A ; Haukka J
Department of Forensic Psychiatry, University of Kuopio and Niuvanniemi Hospital, Department of Clinical Physiology, Kuopio University Hospital, Kuopio, Finland. jari.tiihonen@niuva.fi

BACKGROUND: The introduction of second-generation antipsychotic drugs during the 1990s is widely believed to have adversely affected mortality of patients with schizophrenia. Our aim was to establish the long-term contribution of antipsychotic drugs to mortality in such patients. METHODS: Nationwide registers in Finland were used to compare the cause-specific mortality in 66 881 patients versus the total population (5.2 million) between 1996, and 2006, and to link these data with the use of antipsychotic drugs. We measured the all-cause mortality of patients with schizophrenia in outpatient care during current and cumulative exposure to any antipsychotic drug versus no use of these drugs, and exposure to the six most frequently used antipsychotic drugs compared with perphenazine use. FINDINGS: Although the proportional use of second-generation antipsychotic drugs rose from 13% to 64% during follow-up, the gap in life expectancy between patients with schizophrenia and the general population did not widen between 1996 (25 years), and 2006 (22.5 years). Compared with current use of perphenazine, the highest risk for overall mortality was recorded for quetiapine (adjusted hazard ratio [HR] 1.41, 95% CI 1.09-1.82), and the lowest risk for clozapine (0.74, 0.60-0.91; p=0.0045 for the difference between clozapine vs perphenazine, and p<0.0001 for all other antipsychotic drugs). Long-term cumulative exposure (7-11 years) to any antipsychotic treatment was associated with lower mortality than was no drug use (0.81, 0.77-0.84). In patients with one or more filled prescription for an antipsychotic drug, an inverse relation between mortality and duration of cumulative use was noted (HR for trend per exposure year 0.991; 0.985-0.997). INTERPRETATION: Long-term treatment with antipsychotic drugs is associated with lower mortality compared with no antipsychotic use. Second-generation drugs are a highly heterogeneous group, and clozapine seems to be associated with a substantially lower mortality than any other antipsychotics. Restrictions on the use of clozapine should be reassessed. FUNDING: Annual EVO Financing (Special government subsidies from the Ministry of Health and Welfare, Finland).

PreMedline Identifier:19595447

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

3 comments:

tal said...

Abram Hoffer said "For schizophrenics, the natural recovery rate is 50%. With orthomolecular medicine, the recovery rate is 90%. With drugs, it is 10%. If you use just drugs, you won't get well." Please read the linked article below:

Vitamin B-3: Niacin and Its Amide by A. Hoffer, M.D., Ph.D.
http://www.doctoryourself.com/hoffer_niacin.html

herbalYODA said...

Thank you for posting your comment about Dr Hoffer. I have been following his work since the late 60s and personally know of people who have recovered from schizophrenia with his methods.
It is tragic that PubMed refuses to allow Orthomolecular Medicine to be included in its index. If more people were able to access this information we would get away from the disease-drug model.

see orthomed.org and othomolecular.org

and http://naturalhealthnews.blogspot.com/2009/11/where-are-niacin-studies-for.html
as well as about 20 other articles here at Natural Health News

HealthyLife said...

Nice post, Interesting Lay Out, and Usefull Information about Health.